Compare Medpace Holdings Inc (MEDP) vs Marvell Technology Inc (MRVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Marvell Technology Inc — how do they compare? Medpace Holdings Inc trades at $519.93 (market cap $15.08B), while Marvell Technology Inc trades at $206.44 (market cap $171.11B). The key difference: Marvell Technology Inc is far larger — about 11.3× Medpace Holdings Inc's market cap, and Marvell Technology Inc pays a 0.12% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | MRVL | |
|---|---|---|
Market Cap | $15.08B | $171.11B |
Sector | Technology | Technology |
52-Week High | $620.59 | $316.43 |
52-Week Low | $308.88 | $62.31 |
Enterprise Value | $14.55B | $172.55B |
Dividend Yield | — | 0.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Marvell Technology (MRVL) trades at $195.28, up 3.5% today, with a bullish technical signal from oscillators but bearish moving averages. Recent earnings have consistently beaten expectations, though the company reported a net loss of $885 million in 2025. Analyst consensus is strongly bullish with an average price target of $275.68, and the stock is positioned in the AI infrastructure sector, with news highlighting its potential in custom chips and networking.
Outlook is positive due to strong analyst support and AI-driven growth prospects, but risks include high valuation multiples, recent net losses, and semiconductor market volatility. The stock offers significant upside if execution matches expectations, yet investors must weigh growth potential against current profitability challenges and industry cyclicality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →
